Solid Biosciences Growth, Revenue, Number of Employees and Funding

Overview

Location:
Boston, MA USA
Total Funding:$217.5M
Industry:Biotech
Founded:2013
Lead Investor(s):J.P. Morgan, Goldman Sachs & Co. LLC
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Solid Biosciences's estimated revenue is currently $12.4M per year.
  • Solid Biosciences received $133.7M in venture funding in February 2018.
  • Solid Biosciences's estimated revenue per employee is $86111
  • Solid Biosciences's total funding is $217.5M.

Employee Data

  • Solid Biosciences has 144 Employees.
  • Solid Biosciences grew their employee count by 21% last year.
  • Solid Biosciences currently has 1 job openings.

Executive Contacts

NameTitle
Debra SegalVice President, Regulatory Affairs
Kristy BrownAssociate Director R&D
Christine KitsosDirector, Head of Analytical Development
Alvaro AmorrortuChief Operating Officer
Susan RedicanSenior Director, Clinical Operations
Peter PechanSenior Director, Vector Biology
Robert LuVP, Process Development
Gonzalo MiletAssociate Director, Manufacturing
Alexey SereginAssociate Director, Vector Biology
Li-Chun WangSenior Director, Regulatory Affairs CMC

What Is Solid Biosciences?

Solid Biosciences (Solid) is a Cambridge, MA based biotech company singularly focused on developing treatments and cures for Duchenne muscular dystrophy (DMD). Solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. Condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of DMD.

keywords:Biotechnology,Healthcare,Pharmaceuticals

144

Number of Employees

$12.4M

Revenue (est)

1

Current Jobs

21%

Employee Growth %

$217.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$6.7M4659%
Tango Therapeut...
$8.4M5841%$55M
Compass Therape...
$14.7M10215%
Hamilton Storag...
$13.6M949%
Alnylam Pharmac...
$74.9M122831%$417.5M
Axcella
$8.2M5719%
Berkshire Corpo...
$10.7M7412%
Repligen Corpor...
$47M32422%$242.6M
Allena Pharmace...
$6M5019%$93M
ABclonal Techno...
$7.9M5531%

Solid Biosciences News

31-Aug-19 - Citi: Solid Biosciences Rally Unsupported By Fundamentals

Following the near 100% rally in shares of Solid Biosciences Inc (NASDAQ: SLDB) in August, one Citigroup analyst said the stock price is ...

31-Aug-19 - Solid Biosciences Stock Falls as Analyst Says Nothing Fundamental Has Changed

Shares of the gene therapy biotech specialist Solid Biosciences slid Thursday morning as an analyst at Citi Research argued that it was time to ...

31-Aug-19 - Solid Biosciences Inc. (NasdaqGS:SLDB) Quant Signals Under The Gun as EV Hits 375097

Investors are constantly examining different company financial indicators to assess trading opportunities. Solid Biosciences Inc.

Solid Biosciences Funding

DateAmountRoundLead InvestorsReference
2015-11-04$42.5MBerceptive Advisors, LLCArticle
2017-03-31$50.0MCRA Capital ManagementArticle
2018-02-01$133.7MUndisclosedJ.P. MorganArticle